Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date

Alopecia areata (AA) is a chronic, tissue-specific autoimmune disorder, characterized by non-scaring hair loss, with a global prevalence of approximately 2%. Typically, it affects a young population, with initial onset frequently occurring before the age of 30 years. Even though the exact pathogenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Faria, Sofia, Freitas, Egídio, Torres, Tiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537548/
https://www.ncbi.nlm.nih.gov/pubmed/37781168
http://dx.doi.org/10.7573/dic.2023-6-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537548/
https://www.ncbi.nlm.nih.gov/pubmed/37781168
http://dx.doi.org/10.7573/dic.2023-6-2

Ejemplares similares